These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 21806380)

  • 21. Rapid discovery and structure-activity profiling of novel inhibitors of human immunodeficiency virus type 1 protease enabled by the copper(I)-catalyzed synthesis of 1,2,3-triazoles and their further functionalization.
    Whiting M; Tripp JC; Lin YC; Lindstrom W; Olson AJ; Elder JH; Sharpless KB; Fokin VV
    J Med Chem; 2006 Dec; 49(26):7697-710. PubMed ID: 17181152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent developments of peptidomimetic HIV-1 protease inhibitors.
    Qiu X; Liu ZP
    Curr Med Chem; 2011; 18(29):4513-37. PubMed ID: 21864279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design of HIV-1 Protease Inhibitors with Amino-bis-tetrahydrofuran Derivatives as P2-Ligands to Enhance Backbone-Binding Interactions: Synthesis, Biological Evaluation, and Protein-Ligand X-ray Studies.
    Ghosh AK; Martyr CD; Osswald HL; Sheri VR; Kassekert LA; Chen S; Agniswamy J; Wang YF; Hayashi H; Aoki M; Weber IT; Mitsuya H
    J Med Chem; 2015 Sep; 58(17):6994-7006. PubMed ID: 26306007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disubstituted Bis-THF Moieties as New P2 Ligands in Nonpeptidal HIV-1 Protease Inhibitors (II).
    Hohlfeld K; Wegner JK; Kesteleyn B; Linclau B; Unge J
    J Med Chem; 2015 May; 58(9):4029-38. PubMed ID: 25897791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. From SAR to comparative QSAR: role of hydrophobicity in the design of 4-hydroxy-5,6-dihydropyran-2-ones HIV-1 protease inhibitors.
    Bhhatarai B; Garg R
    Bioorg Med Chem; 2005 Jun; 13(12):4078-84. PubMed ID: 15911321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of triazolamers as active site inhibitors of HIV-1 protease.
    Jochim AL; Miller SE; Angelo NG; Arora PS
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6023-6. PubMed ID: 19800230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potent inhibitors of the HIV-1 protease incorporating cyclic urea P1-P2 scaffold.
    Kazmierski WM; Furfine E; Gray-Nunez Y; Spaltenstein A; Wright L
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5685-7. PubMed ID: 15482948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of protease inhibitors and the fight with drug-resistant HIV-1 variants.
    Mitsuya H; Maeda K; Das D; Ghosh AK
    Adv Pharmacol; 2008; 56():169-97. PubMed ID: 18086412
    [No Abstract]   [Full Text] [Related]  

  • 29. Synthesis and biological evaluation of novel small non-peptidic HIV-1 PIs: the benzothiophene ring as an effective moiety.
    Chiummiento L; Funicello M; Lupattelli P; Tramutola F; Berti F; Marino-Merlo F
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2948-50. PubMed ID: 22414613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-based design of HIV-1 protease inhibitors: replacement of two amides and a 10 pi-aromatic system by a fused bis-tetrahydrofuran.
    Ghosh AK; Thompson WJ; Fitzgerald PM; Culberson JC; Axel MG; McKee SP; Huff JR; Anderson PS
    J Med Chem; 1994 Aug; 37(16):2506-8. PubMed ID: 8057296
    [No Abstract]   [Full Text] [Related]  

  • 31. Design, biologic evaluation, and SAR of novel pseudo-peptide incorporating benzheterocycles as HIV-1 protease inhibitors.
    He M; Zhang H; Yao X; Eckart M; Zuo E; Yang M
    Chem Biol Drug Des; 2010 Aug; 76(2):174-80. PubMed ID: 20572811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is resistance futile?
    Kutilek VD; Sheeter DA; Elder JH; Torbett BE
    Curr Drug Targets Infect Disord; 2003 Dec; 3(4):295-309. PubMed ID: 14754431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibitors of HIV protease: unique non-peptide active site templates.
    Tait BD; Domagala J; Ellsworth EL; Ferguson D; Gajda C; Hupe D; Lunney EA; Tummino PJ
    J Mol Recognit; 1996; 9(2):139-42. PubMed ID: 8877805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in non-peptidomimetic HIV protease inhibitors.
    Pang X; Liu Z; Zhai G
    Curr Med Chem; 2014 Jun; 21(17):1997-2011. PubMed ID: 24533811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of next generation inhibitors of HIV protease.
    Spaltenstein A; Kazmierski WM; Miller JF; Samano V
    Curr Top Med Chem; 2005; 5(16):1589-607. PubMed ID: 16375744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
    Ghosh AK; Kincaid JF; Walters DE; Chen Y; Chaudhuri NC; Thompson WJ; Culberson C; Fitzgerald PM; Lee HY; McKee SP; Munson PM; Duong TT; Darke PL; Zugay JA; Schleif WA; Axel MG; Lin J; Huff JR
    J Med Chem; 1996 Aug; 39(17):3278-90. PubMed ID: 8765511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peptidomimetic inhibitors of HIV protease.
    Randolph JT; DeGoey DA
    Curr Top Med Chem; 2004; 4(10):1079-95. PubMed ID: 15193140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 3-Alkanoyl-5-hydroxymethyl tetronic acid homologues: new inhibitors of HIV-1 protease. II. Structure determination.
    Roggo BE; Hug P; Moss S; Raschdorf F; Peter HH
    J Antibiot (Tokyo); 1994 Feb; 47(2):143-7. PubMed ID: 8150708
    [No Abstract]   [Full Text] [Related]  

  • 39. GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.
    Amano M; Tojo Y; Salcedo-Gómez PM; Campbell JR; Das D; Aoki M; Xu CX; Rao KV; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2013 May; 57(5):2036-46. PubMed ID: 23403426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Viral resistance to protease inhibitors.
    Smart T
    GMHC Treat Issues; 1995 Jun; 9(6):1, 4-5. PubMed ID: 11362685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.